This phase 1 dose escalation study for recurrent GBM found no dose limiting toxicity for 35 Gy in 10 fractions or 42 Gy in 12 fractions, but 3 of 5 patients had dose limiting neurocognitive toxicity without tumor progression at a dose of 49 Gy in 14 fractions. | Mathen, Pract Radiat Oncol 2026
